Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

European journal of cancer (Oxford, England : 1990)·2026

Same author

ASO Visual Abstract: Correlations between the Histological Growth Patterns of Peritoneal and Liver Metastases from Colorectal Cancer.

Annals of surgical oncology·2026

Same author

Correlations Between the Histologic Growth Patterns of Peritoneal and Liver Metastases From Colorectal Cancer.

Annals of surgical oncology·2026

Same author

Quantitative accuracy of <sup>177</sup>Lu SPECT/CT imaging using ring-shaped CZT versus dual-head NaI systems.

EJNMMI physics·2026

Same author

Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam Radiotherapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

<sup>211</sup>At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.

European journal of nuclear medicine and molecular imaging·2026

Search research articles

Related Experiment Video

Updated: Apr 22, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

FAP-targeted PET Imaging in Peritoneal Carcinomatosis.

Ayça Arçay Öztürk¹, Gabriel Liberale², Patrick Flamen¹

¹Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium.

The British Journal of Radiology

|April 21, 2026

Summary

Fibroblast activation protein inhibitor (FAPI) PET/CT offers superior imaging of peritoneal carcinomatosis compared to Fluorine-18([18F])-FDG PET/CT. This advanced imaging improves detection of peritoneal disease extent, aiding clinical decisions and potentially reducing understaging.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Apr 22, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Area of Science:

Oncology
Nuclear Medicine
Radiology

Background:

Peritoneal carcinomatosis significantly impacts prognosis and surgical options for abdominopelvic cancers.
Conventional imaging like CT/MRI and Fluorine-18([18F])-FDG PET/CT often fail to accurately assess the full extent of peritoneal disease.
Small, flat, or low-FDG-avid peritoneal implants are particularly challenging to detect with current methods.

Purpose of the Study:

To evaluate the diagnostic performance of Fibroblast Activation Protein Inhibitor (FAPI) PET/CT for peritoneal carcinomatosis.
To compare FAPI PET/CT with conventional imaging modalities, specifically FDG PET/CT.
To assess the potential impact of FAPI PET/CT on clinical decision-making regarding patient management.

Main Methods:

Review of head-to-head studies and meta-analyses comparing FAPI PET/CT and FDG PET/CT.
Analysis of imaging characteristics, including tumour uptake and tumour-to-background ratios.
Assessment of diagnostic sensitivity and impact on the peritoneal cancer index.

Main Results:

FAPI PET/CT consistently shows higher tumour uptake and tumour-to-background ratios in peritoneal lesions compared to FDG PET/CT.
FAPI PET/CT demonstrates higher diagnostic sensitivity for detecting peritoneal carcinomatosis than FDG PET/CT.
Improved mapping of peritoneal disease via FAPI PET/CT leads to a more accurate peritoneal cancer index.

Conclusions:

FAPI PET/CT represents a significant advancement in imaging peritoneal carcinomatosis, outperforming FDG PET/CT.
Enhanced visualization of peritoneal metastases with FAPI PET/CT can refine patient selection for surgery and therapies.
Further prospective trials are needed to establish optimal indications and confirm outcome benefits, addressing current limitations like single-center data and heterogeneous standards.